Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Xenon Pharmaceuticals (NASDAQ:XENE) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.05, FiscalAI reports. During the same quarter last year, the firm earned ($1.07) EPS.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Atera demand significantly exceeded expectations, with booked orders already well above the approximately 40 instruments the company expects to ship in 2026. Management said demand—not customer interest—is the constraint, with manufacturing capacity limiting near-term shipments.
• 10x raised its 2026 revenue outlook to $610 million–$630 million, implying 2%–5% underlying growth excluding settlement revenue. Second-quarter revenue was $151 million, or $149.4 million excluding the $1.6 million Takara settlement, while gross margin improved to 74%.
• Total instrument revenue fell 47% year over year, as customers delayed Xenium and Visium purchases ahead of Atera’s launch. Management expects a modest sequential revenue decline in Q3 from continued spatial transition effects before a significant Q4 increase as Atera shipments ramp.
• Core consumables remained resilient, with total consumables revenue up 7%, spatial consumables up 16%, and single-cell reaction volumes growing at a double-digit rate driven by Flex Apex. Management also characterized AI-driven demand for high-quality single-cell and spatial data as a significant long-term structural tailwind.
• Academic funding conditions remain tenuous; grant sentiment is improving, but funding has not yet translated consistently into purchasing because of allocation delays, oversight, and order-processing bottlenecks. The company’s guidance assumes the current macro environment persists rather than any meaningful academic-market recovery.

Xenon Pharmaceuticals Price Performance

XENE traded up $0.25 on Thursday, reaching $64.55. 435,008 shares of the company’s stock were exchanged, compared to its average volume of 912,216. Xenon Pharmaceuticals has a twelve month low of $32.78 and a twelve month high of $72.66. The stock has a market cap of $6.24 billion, a PE ratio of -13.73 and a beta of 0.62. The stock’s fifty day moving average price is $60.06 and its 200-day moving average price is $54.14.

Insider Transactions at Xenon Pharmaceuticals

In other news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gary Patou sold 1,322 shares of the stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director directly owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The SEC filing for this sale provides additional information. 2.91% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at $32,000. Kestra Advisory Services LLC purchased a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth $33,000. Osaic Holdings Inc. raised its holdings in shares of Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at about $43,000. Finally, State of Wyoming boosted its position in shares of Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 350 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on XENE shares. JPMorgan Chase & Co. boosted their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Needham & Company LLC lowered their price objective on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 price objective on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Royal Bank Of Canada raised their target price on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $77.20.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.